# Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients

Source: https://onco.cc/trials/nct06284590/  
OnCo record `nct06284590` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab in melanoma, run by Philogen S.p.A., now recruiting.

## Summary

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients is a phase 2 interventional study registered as NCT06284590 by Philogen S.p.A., with 162 participants planned, started 2024-07-12 and due to reach its primary completion in 2028-07. Interventions recorded: L19IL2, L19TNF, L19IL2/L19TNF, KEYTRUDA®. Conditions listed: Melanoma Stage III, Melanoma Stage IV. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06284590
- Phase: 2
- Setting: A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination With Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients With Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and With Presence of Injectable Metastases
- Sponsor: Philogen S.p.A.
- Enrolled: 162

## Sources

- ClinicalTrials.gov NCT06284590: https://clinicaltrials.gov/study/NCT06284590

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Philogen S.p.A.](https://onco.cc/companies/philogen-s-p-a/)

---
JSON: https://onco.cc/api/v1/entities/nct06284590.json